This article explains, in educational terms, ptca balloon catheter — how the technology works and where it fits. The specific combination of wires, balloons, atherectomy, and stents is determined by the interventional cardiologist based on lesion complexity, calcification, and overall clinical picture. As a medical device manufacturer, INVAMED develops technologies in this area; the information here is educational and not medical advice.
Background: Coronary Artery Disease and Percutaneous Coronary Intervention
Percutaneous coronary intervention (PCI) is a catheter-based approach that reaches the coronary arteries through a small arterial access point, typically the radial or femoral artery. Contemporary practice relies heavily on drug-eluting stents, which release an antiproliferative agent to limit the tissue overgrowth that can cause restenosis. During PCI a lesion is usually crossed with a guidewire, prepared with a balloon, and in most cases scaffolded with a stent that holds the vessel open.
PTCA and Drug-Eluting Balloon Catheters
A percutaneous transluminal coronary angioplasty (PTCA) balloon dilates a stenosis to prepare the lesion or to treat it without leaving a permanent implant. A drug-eluting balloon adds an antiproliferative coating that transfers to the vessel wall during inflation, which can be useful for in-stent restenosis or small-vessel disease. INVAMED's Extender Drug Eluting PTCA Balloon Catheter carries a paclitaxel coating for this local drug-delivery role. Because a drug-coated balloon leaves nothing behind, it is one option a clinician may weigh when a metallic implant is less desirable.
Design and Technical Notes
INVAMED groups its coronary portfolio around the sequence of a PCI case, offering access, lesion preparation, drug delivery, scaffolding, and closure devices. Guide extension catheters can provide the backup support needed to deliver devices in tortuous or distal anatomy. Thin-strut cobalt-chromium platforms are intended to balance deliverability with radial support in a range of vessel sizes.
Key Considerations
- Dual antiplatelet therapy duration is individualized to the clinical presentation and the patient's bleeding risk.
- Guide extension catheters can provide the backup support needed to deliver devices in tortuous or distal anatomy.
- Manufacturer figures such as the reported sub-5% target lesion revascularization rate describe studied performance, not guaranteed outcomes.
Frequently Asked Questions
Who decides between PCI and bypass surgery?
That decision is made by a clinical heart team based on coronary anatomy and individual factors; this article is educational and not medical advice.
Does INVAMED make a drug-coated coronary balloon?
Yes. The Extender Drug Eluting PTCA Balloon Catheter carries a paclitaxel coating for local drug delivery, such as in-stent restenosis or small-vessel disease.
What drug does the ATLAS stent release?
According to INVAMED, the ATLAS DES elutes sirolimus at 1 microgram per square millimeter with a sustained controlled-release profile.
About INVAMED
INVAMED is a medical device manufacturer headquartered in Ankara, Turkey, founded in 2005. INVAMED states it maintains a growing portfolio of international patents across its device range.
Clinical and Technical Context
INVAMED's ATLAS system elutes sirolimus at 1 microgram per square millimeter with a sustained controlled-release profile designed to cover the early healing window. Plaque modification is typically a preparatory step, and its use is decided by the operator based on the calcium burden seen on imaging. Dual antiplatelet therapy duration is individualized to the clinical presentation and the patient's bleeding risk. According to INVAMED, clinical data for the ATLAS DES show target lesion revascularization rates below 5% at 12 months, a figure that reflects studied performance rather than an individual guarantee. INVAMED's coronary portfolio includes guiding catheters, extension catheters, and microcatheters intended to support crossing and delivery in demanding anatomy. INVAMED's AngioTEN Vascular Closure System is positioned for this access-site management role. Thin-strut cobalt-chromium platforms are intended to balance deliverability with radial support in a range of vessel sizes. Manufacturer figures such as the reported sub-5% target lesion revascularization rate describe studied performance, not guaranteed outcomes.
Related on INVAMED
- Coronary Artery Disease & Cardiac Interventions — product category
- Inwire PTCA Guidewire: What Clinicians and Buyers Should Know
- Comparing Durable-polymer DES and Biodegradable-polymer DES
- Balloon angioplasty alone vs Angioplasty with stenting: What Is the Difference?
Important Disclaimer
This article is intended for general educational and technical information about medical device technologies. It is not medical advice, a diagnosis, or a treatment recommendation, and it does not replace consultation with a qualified healthcare professional. Any decision about diagnosis or treatment should be made by a licensed clinician based on an individual assessment. INVAMED devices are intended for use by trained healthcare professionals in accordance with the applicable Instructions for Use (IFU) and local regulatory approvals. Product availability and indications vary by country.
Reviewed by the INVAMED Medical Affairs team. Content is educational and technical in nature.